Apology for Exclusion: Public Health Tobacco Control Act 2023

Regulations by 2FIRSTS.ai
Dec.25.2023
Apology for Exclusion: Public Health Tobacco Control Act 2023
Malaysia's Health Minister, Datuk Seri Dr Adham Baba, apologizes for not including the "Gen Excluded from Smoking" policy in the Public Health Tobacco Control Act 2023.

According to a report by the Malaysian media outlet Borneo Post on January 24th, the Minister of Health, Datuk Seri Dr Adham Baba, admitted that he does not have the authority to implement a nationwide smoking ban as he is not the Minister of Religion. However, he emphasized his responsibility as the Minister of Health to ensure that smokers and their actions do not harm non-smokers, as smoking is detrimental to health.

 

Zulfikar also serves as the Chief Strategist of the Integrity Party. At the Integrity Party's 2023 National Congress, he responded to representatives' proposal, the "2023 Public Health Tobacco Control Bill." He once again apologized to party delegates for not including the "Generation Excluded from Smoking" (GEG) policy in the legislation, which aimed at achieving a smoke-free generation.

 

On the 30th of last month, the "2023 Public Health Tobacco Product Control Bill" was passed in the lower house of Parliament through a voice vote. However, it is worth noting that this bill has removed the previously set GEG policy, which prohibited the smoking and possession of tobacco products for individuals born after 2007. The policy has now been replaced with a ban on individuals under the age of 18 purchasing tobacco products, tobacco alternatives, and smoking devices.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

BAT CEO Says 2026 Return to Growth Hinges on U.S. Enforcement, Highlights Oral Leadership
BAT CEO Says 2026 Return to Growth Hinges on U.S. Enforcement, Highlights Oral Leadership
British American Tobacco said 2026 will mark a return to its mid-term growth algorithm, but CEO Tadeu Marroco stressed that deliverywill depend heavily on enforcement against illicit vapour products in the United States. Speaking at the FY2025 results call, he positioned Modern Oral as the company’s primary structural growth engine, reframed accelerating cigarette declines through “poly-usage,” and reinforced capital discipline with an expanded share buyback plan.
Feb.12
FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
Feb.11
UK Smoke-Free Generation Plan Backed by Both Houses of Parliament
UK Smoke-Free Generation Plan Backed by Both Houses of Parliament
Plans to create a smoke-free generation have received backing from both Houses of Parliament in the UK. On Monday, peers approved the Tobacco and Vapes Bill at its third reading, with the measure aiming to prevent anyone currently aged 17 or younger from ever buying cigarettes.
Mar.11 by 2FIRSTS.ai
Virginia Attorney General Backs Vape Enforcement Act Limiting Sales to FDA-Authorized or Pending Products
Virginia Attorney General Backs Vape Enforcement Act Limiting Sales to FDA-Authorized or Pending Products
Virginia Attorney General Jay Jones is backing new vape enforcement legislation that he said would do more than warn people about the dangers of vaping. The proposal would tighten rules on which products can be sold and increase enforcement aimed at keeping vapes out of the hands of young people.
Mar.24 by 2FIRSTS.ai
Philip Morris and BAT’s Nicoventures Win EPO Appeal to Revoke VMR Vape Patent
Philip Morris and BAT’s Nicoventures Win EPO Appeal to Revoke VMR Vape Patent
The EPO Technical Board of Appeal 3.2.02 (T 1319/24) revoked VMR Products LLC’s EP3613453 “VAPORIZER” patent after finding that a 2012 YouTube video of the Innokin iTaste VV (D3) disclosed the claimed electrical contact arrangement. Opponents Nicoventures Trading Ltd (BAT subsidiary) and Philip Morris Products S.A. prevailed.
BATPMI
Feb.17
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11